India’s Risk-Based Inspection Plan: Well Begun?
This article was originally published in PharmAsia News
Executive Summary
India's CDSCO is taking definitive steps to strengthen the regulatory regime and enforcement, including across areas such as data integrity, against the backdrop of industry's patchy manufacturing compliance.
You may also be interested in...
India Sets Out Modalities Of Perpetual Licensing Initiative
India has outlined key aspects of its recently introduced perpetual licensing system, including initial modalities around joint inspections of manufacturing units by central and state drug inspectors.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.